Is it safe to perform percutaneous treatment in acute pulmonary thrombosis?

Courtesy of Dr. Carlos Fava

Pulmonary embolismMassive and submassive pulmonary embolism (PE) has traditionally been treated with anticoagulation and catheter direct thrombolysis (CDT), but the safety and efficacy of this treatment has not been yet properly assessed.

 

The study analyzed 137 patients presenting acute PE massive or submassive. All patients received CTD associated to heparin by direct infusion or ultrasound assisted catheter. Infusion time was left to operators’ criteria.

 

Age was 59, half were men, 26% had a history of thromboembolism, 24% were diabetic, 82% had right ventricle compromise, and 12% had massive PE.

 

82% of cases presented bilateral PE, other 14% presented right pulmonary thrombosis, and the remaining 4% presented left pulmonary thrombosis. Thrombolysis was often ultrasound assisted (84%).

 

After thrombolysis, PASP decreased 19±15 mmHg and vena cava filters were implanted in 45% of patients.

 

5 patients died (all with massive PE). 13 patients presented major bleeding or vascular lesions; 4 presented bleeding (2 intracranial and 2 gastrointestinal), while other 6 required transfusions. There were no differences in thrombolysis technique.

 

Factors associated to complications were elderly age, massive PE and vena cava filter implantation.

 

In addition, a meta-analyzis of 16 studies with 860 patients presenting PE undergoing CDT (including this study) was carried out. Mean age was 60 (54-61), half of patients were men, and 21.6% presented massive PE.

 

After thrombolysis, PE decreased 15 mmHg. Major bleeding or vascular complications rate was 4.65%, intracranial bleeding was 0.35% and mortality was 3.4% (12.9% in massive PE and 0.74% in submassive).

 

Conclusion

Catheter direct thrombolysis is associated to low complications rate. Randomized studies should be carried out to assess its efficacy relative to anticoagulation alone.

 

Commentary

This analyzis –with a large number of patients− disregards the fact that it is possible to treat PE percutaneously, not just by injecting thrombolytics, but also by safely extracting thrombi.

 

Perhaps a stronger commitment to this condition might improve outcomes and help develop better devices or techniques.

 

Courtesy of Dr. Carlos Fava

 

Original Title: Safety of Catheter-Direct Thrombolysis for Massive and Submassive Pulmonary Embolism: Results for Massive and Submassive Pulmonary Embolism.

Reference: Tyler Blommer, et al. Catheterization and Cardiovasacular Intervention 2017:89:754-760.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Download the Official SOLACI-CACI 2024 Congress APP

  DOWNLOAD THE OFFICIAL APP OF SOLACI-CACI 2024 Next Wednesday marks the beginning of SOLACI-CACI 2024! Download the Congress APP and discover the unmissable program of the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...